STM JOURNALS

Research & Reviews: A Journal of
Immunology

https://journals.stmjournals.com/rrjoi

ISSN: 2277-6206 (Online)
ISSN: 2349-1280 (Print)
Volume 14, Issue 2, 2024
May–August
DOI (Journal): 10.37591/RRJoI

Review RRJoI

Wiskott-Aldrich Syndrome: A Comprehensive Guide

Kamini Sao*

Abstract

Wiskott-Aldrich Syndrome (WAS) is an uncommon genetic disorder inherited through the X chromosome, marked by a combination of immune system deficiencies, eczema, and low platelet counts. This syndrome primarily affects males, leading to significant morbidity and mortality due to recurrent infections, bleeding complications, and autoimmune diseases. Mutations in the WAS gene disrupt the production of the Wiskott-Aldrich Syndrome protein (WASp), crucial for the functioning of immune cells and platelet formation. Diagnostic approaches include clinical evaluation, laboratory tests, and genetic analysis, with flow cytometry and molecular genetic testing playing pivotal roles. Current treatment strategies encompass hematopoietic stem cell transplantation (HSCT), gene therapy, and supportive care, aiming to improve immune function and manage symptoms. Recent developments in gene therapy show encouraging potential for achieving sustained remission over an extended period. Additionally, the role of supportive therapies, such as prophylactic antibiotics, immunoglobulin replacement, and careful management of eczema and bleeding, are critical in improving patient outcomes. Emerging research into targeted therapies and the development of better HSCT protocols continue to enhance the prognosis for WAS patients. This review provides a comprehensive overview of the clinical manifestations, diagnostic methodologies, and emerging treatment options for Wiskott-Aldrich Syndrome, emphasizing the importance of early diagnosis and intervention, and the potential for future therapeutic breakthroughs.

Keywords: Wiskott-Aldrich Syndrome, immunodeficiency, thrombocytopenia, WAS gene, hematopoietic stem cell transplantation, gene therapy, immunodeficiency disorders, pediatric immunology, genetic mutations

INTRODUCTION

Wiskott-Aldrich Syndrome (WAS) is a rare genetic immunodeficiency disorder that impairs a child's immune system functionality and hinders the bone marrow's ability to produce platelets, making the child susceptible to bleeding. Predominantly affecting males, WAS is seen in 1 to 10 out of every 1 million boys, according to the National Institutes of Health [1].

Wiskott-Aldrich Syndrome (WAS) is a rare genetic disorder linked to the X chromosome, featuring a combination of immune deficiency, low platelet counts, and eczema. It results from mutations in the gene responsible for producing the Wiskott-Aldrich syndrome protein (WASp), affecting immune function and causing immunodeficiency. The clinical presentation of the disease varies widely depending on the specific gene mutations, ranging from a severe phenotype (classic WAS) to milder forms such as X-linked thrombocytopenia (XLT) and X-linked neutropenia [2].

The human immune system functions as a vigilant guardian, constantly patrolling and defending the body against various threats such as bacteria, viruses, and parasites. Both the blood and immune system originate from the bone marrow of

*__Author for Correspondence__
Kamini Sao
E-mail: kaminisao@gmail.com

Assistant Professor, Department of Child Health Nursing Kasturba Nursing College, Sevagram, Maharashtra, India

Received Date: May 20, 2024
Accepted Date: June 12, 2024
Published Date: August 16, 2024

Citation: Kamini Sao. Wiskott-Aldrich Syndrome: A Comprehensive Guide. Research & Reviews: A Journal of Immunology. 2024; 14(2): 39–46p.

a developing fetus. Bone marrow stem cells differentiate into various blood cells, including platelets, which are essential for controlling bleeding. Additionally, these stem cells mature into critical immune cells: T cells, which identify and attack perceived invaders, and B cells, which produce antibodies to fight infections [2].

Moreover, stem cells generate various types of white blood cells essential for clearing infections.

INCIDENCES

This X-linked disorder occurs in approximately 1 in every 100,000 live male births and is not associated with any particular ethnic or geographical group. Due to its presentation primarily in males, it may go undiagnosed or misdiagnosed, sometimes mistaken for idiopathic thrombocytopenic purpura [3,4].

Wiskott-Aldrich syndrome (WAS) manifests in more than one form. Most affected boys have the "classic" form of the syndrome, but some exhibit a milder variant known as X-linked thrombocytopenia (XLT). Both forms result from defects in the same gene, but XLT symptoms are typically less severe [5].

Children with XLT usually have small, low-number platelets, leading to easy bleeding and bruising without the more severe complications seen in classic WAS. It can be difficult to predict whether a male infant with a WAS gene mutation will develop the severe form of the disease or X-linked thrombocytopenia (XLT). Additionally, individuals with XLT may still develop complications typical of classic WAS as they age. Therefore, regular monitoring by healthcare providers and specialists is essential for managing both conditions [6].

ETIOLOGY

Wiskott-Aldrich syndrome (WAS) results from mutations in the WAS gene, which produces the WASP protein present in all blood cells. WASP plays a critical role in transmitting signals from the cell surface to the actin cytoskeleton, crucial for cell movement and adhesion, particularly in white blood cells during immune responses. Mutations in the WAS gene result in non-functional WASP, disrupting actin cytoskeleton function in developing blood cells. This deficiency impairs white blood cells' ability to respond to their environment and form immune synapses, compromising immune function. Additionally, platelets lacking functional WASP exhibit reduced size and premature death, contributing to microthrombocytopenia. Due to their common genetic origin, disorders such as X-linked thrombocytopenia and severe congenital neutropenia are classified as related to Wiskott-Aldrich syndrome (WAS) [7,8].

FORMS OF WISKOTT-ALDRICH SYNDROME [9-11]

1. *Classic (Severe) Wiskott-Aldrich Syndrome (WAS):* This severe phenotype of WAS manifests in early childhood. Boys with the condition commonly show signs of bleeding tendency from low platelet levels, frequent infections caused by bacteria, viruses, and fungi, and severe eczema. Chronic eczema often leads to lymphadenopathy, and hepatosplenomegaly is common. Individuals with classic WAS are prone to developing autoimmune disorders and malignancies, such as lymphoma, which often result in early mortality.
2. *X-linked Neutropenia (XLN):* XLN primarily presents as congenital neutropenia, characterized by infections typical of neutropenia and sometimes infections linked to lymphocyte dysfunction. Patients with XLN also have an increased risk of developing myelodysplasia.
3. *X-linked Thrombocytopenia (XLT):* XLT is marked by congenital thrombocytopenia, which can be intermittent (IXLT). Eczema is generally mild in these patients.
4. Although X-linked thrombocytopenia (XLT) generally follows a mild course with favorable long-term outcomes, there remains an increased but reduced risk compared to classic WAS for severe complications such as life-threatening infections (especially after spleen removal), significant bleeding, autoimmune issues, and cancer. It is important to assess WASP expression and mutations in the WAS gene in any male showing thrombocytopenia with small platelets.

PATHOPHYSIOLOGY [12-14]

Wiskott-Aldrich syndrome (WAS) stems from an X-linked genetic flaw in the WAS gene, located on the X chromosome's short arm at position Xp11.22-23. This gene produces the Wiskott-Aldrich protein (WASP), a 502-amino acid protein found in the cytoplasm of non-red blood cell hematopoietic cells. More than 300 mutations in the WAS gene have been identified, with missense mutations being the most prevalent, followed by nonsense, splice site, and small deletion mutations. These various genetic mutations lead to a broad spectrum of clinical manifestations, ranging from severe classic WAS to less severe conditions like X-linked thrombocytopenia (XLT) and X-linked neutropenia.

WASP functions in non-erythroid hematopoietic cells, linking signaling pathways to the movement of actin filaments within the cytoskeleton. The actin cytoskeleton plays a vital role in cell shape, mobility, and a range of cellular processes such as growth, cell division, internalization of substances, release of substances, and the creation of immune connections between T cells and antigen-presenting cells. In WAS, defective cytoskeletal reorganization leads to T cell dysfunction, impaired migration, adhesion, and abnormal synapse formation. This affects B cell homeostasis, resulting in selective depletion of certain B cell populations and increased cell death over time. Although natural killer (NK) cell numbers are normal or increased, their cytotoxicity is impaired due to defective immunologic synapse formation. Interleukin-2 can partially restore NK cell function by inducing the expression of a related protein. Additionally, invariant natural killer T cells are absent in WAS and XLT, increasing the risk of autoimmunity and cancer.

Autoimmunity in WAS is driven by multiple mechanisms, including inadequate regulatory T cell function, loss of B cell tolerance, expansion of autoreactive B cells, production of autoantibodies, impaired apoptosis of self-reactive lymphocytes, and defective clearance of apoptotic cells, leading to chronic inflammation. WASP-deficient myeloid cells exhibit impaired phagocytosis and chemotaxis, and myeloid cells from patients demonstrate nearly complete failure to assemble actin-rich structures necessary for migration, resulting in impaired response to chemoattractants. Thrombocytopenia in Wiskott-Aldrich syndrome (WAS) results from several factors: enhanced platelet removal, inadequate production of platelets, shortened platelet lifespan due to internal irregularities, and immune-related processes. While "loss-of-function" mutations in the WAS gene cause WAS or XLT, unique "gain-of-function" missense mutations can lead to increased actin polymerization and result in congenital neutropenia.

CLINICAL MANIFESTATIONS [15]

Wiskott-Aldrich syndrome (WAS) is characterized by three main symptoms:

1. *Eczema:* This skin condition causes itchy, dry patches of skin.
2. *Immune deficiency:* White blood cells do not function properly or at all, leading to frequent infections, autoimmune disorders such as rheumatoid arthritis and vasculitis, and an increased risk of anemia, leukemia, or lymphoma.
3. *Bleeding problems (microthrombocytopenia):* Blood clotting is impaired due to a reduced number and smaller size of platelets, resulting in easy bruising, nosebleeds, bloody diarrhea, purpura (bleeding under the skin), and petechiae (a rash with tiny red dots).

Infants affected by Wiskott-Aldrich syndrome due to loss-of-function mutations may show symptoms such as eczema, immune deficiencies, severe oral thrush, and pneumonia.

DIAGNOSIS AND TESTS [16]:

Wiskott-Aldrich syndrome is typically diagnosed during infancy or early childhood through a combination of physical exams and specific tests. Initial signs include bloody diarrhea, unusual bleeding, or bruising. To confirm the diagnosis, healthcare providers may conduct several tests, including:

1. Complete Blood Count (CBC)
2. Genetic blood test
3. Peripheral blood smear

If the diagnosis is not made during infancy, it may become evident in childhood, especially if the child experiences frequent infections due to a compromised immune system. This happens because their body struggles to handle bacteria, viruses, or certain vaccines effectively.

To further evaluate, healthcare providers might perform:

- Blood tests to check if the child can produce antibodies after vaccination, as antibodies trigger an immune response to prevent severe illness.
- Blood tests to assess white blood cells, including T-cells and immunoglobulins, which are crucial for antibody production.

MANAGEMENT

The management of Wiskott-Aldrich syndrome (WAS) aims to address and mitigate the various symptoms and complications of the condition, improve quality of life, and extend survival. Key goals of management include:

Preventing and Treating Infections

- *Prophylactic Antibiotics and Antifungals:* To reduce the risk of infections.
- Intravenous Immunoglobulin (IVIG) therapy aims to enhance the immune system by supplying antibodies.
- *Prompt Treatment of Infections:* Aggressive treatment of bacterial, viral, and fungal infections as they occur.

Managing Bleeding and Thrombocytopenia

- *Platelet Transfusions:* To manage acute bleeding episodes.
- It is advisable to refrain from using aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) as they can worsen bleeding tendencies.
- *Eltrombopag:* A medication that can stimulate platelet production.

Eczema Management

- *Topical Steroids and Moisturizers:* To control skin inflammation and dryness.
- *Avoidance of Triggers:* Identifying and avoiding factors that exacerbate eczema.

Monitoring and Treating Autoimmune Diseases

- *Immunosuppressive Therapy:* Such as corticosteroids or other immunomodulatory agents to manage autoimmune complications.

Screening and Managing Malignancies

- *Regular Monitoring:* For early detection of lymphoma or other cancers.
- *Oncological Treatments:* Appropriate therapies if malignancies develop.

Definitive Treatment

- *Hematopoietic Stem Cell Transplantation (HSCT):* The only curative treatment for WAS, which can correct the underlying immune deficiency and thrombocytopenia. This is most successful when performed early in life.

Supportive Care

- *Regular Follow-Up:* With a multidisciplinary team including immunologists, hematologists, dermatologists, and other specialists as needed.
- *Patient and Family Education:* On the importance of infection prevention, recognizing signs of bleeding, and managing eczema and other symptoms.

Gene Therapy

- *Emerging Treatment:* Gene therapy offers a potential curative approach by correcting the defective WAS gene. This is currently under research and clinical trials but holds promise for the future.

Effective management of WAS requires a comprehensive, multidisciplinary approach tailored to the individual patient's needs and the severity of their symptoms.

PREVENTION

Wiskott-Aldrich syndrome (WAS) is a genetic condition resulting from mutations in the WAS gene. As such, the primary prevention strategy involves genetic counseling and screening to reduce the risk of passing the mutation to offspring. Here are the key approaches to prevent WAS:

Genetic Counseling

- For couples with a family history of Wiskott-Aldrich syndrome (WAS), it is advisable to consult a genetic counselor before starting a pregnancy. A genetic counselor can offer guidance on risks and how the condition may be inherited.
- *Carrier Testing:* Women with a family history of Wiskott-Aldrich syndrome (WAS) can undergo testing to determine if they carry the WAS gene mutation. Because WAS is X-linked, female carriers have a 50% chance of transmitting the mutation to their offspring.

Prenatal Testing

- *Chorionic Villus Sampling (CVS):* Performed around the 10th-13th week of pregnancy, CVS can detect genetic abnormalities, including the WAS gene mutation.
- *Amniocentesis:* Conducted around the 15th-20th week of pregnancy, this test analyzes amniotic fluid to identify genetic disorders.

Preimplantation Genetic Diagnosis (PGD)

- *In Vitro Fertilization (IVF) with PGD:* For couples undergoing IVF, PGD can be used to test embryos for the WAS gene mutation before implantation. This allows only embryos without the mutation to be implanted, thereby preventing the condition in the offspring.

Newborn Screening

- *Early Diagnosis and Intervention:* While this does not prevent the genetic condition itself, early detection through newborn screening programs can allow for prompt medical intervention and management, improving outcomes for affected infants [17].

While these measures can help prevent the birth of children with WAS or ensure early diagnosis, they are primarily focused on families known to be at risk. In families with no known history of WAS, routine genetic screening is not typically performed unless there is a suspicion based on family medical history or other risk factors [18].

PROGNOSIS [19-21]

The outlook and prognosis for individuals with Wiskott-Aldrich syndrome (WAS) can differ widely based on the severity of the condition, the success of treatments, and the timing of diagnosis and intervention. Below are key considerations regarding the prognosis for WAS:

Severity and Variability

Symptoms of Wiskott-Aldrich syndrome (WAS) can vary from mild to severe. The classic form tends to be more severe with increased risk of complications, whereas milder forms such as X-linked thrombocytopenia (XLT) typically have a more favorable outlook.

Infection Risk

Without treatment, individuals with WAS are at high risk for frequent, severe infections due to immune deficiency. Effective management of infections with prophylactic antibiotics, immunoglobulin therapy, and prompt treatment can improve outcomes.

Bleeding Complications

Thrombocytopenia can lead to significant bleeding issues, including easy bruising, nosebleeds, and bleeding in internal organs. Proper management with platelet transfusions and medications like eltrombopag can mitigate these risks.

Autoimmune Disorders and Cancer

People with Wiskott-Aldrich syndrome (WAS) are at higher risk of developing autoimmune conditions and cancers, particularly lymphoma. Regular monitoring and timely intervention are essential for managing these risks effectively.

Hematopoietic Stem Cell Transplantation (HSCT)

Currently, hematopoietic stem cell transplantation (HSCT) is the sole curative treatment for Wiskott-Aldrich syndrome (WAS). It can correct the underlying immune deficiency and thrombocytopenia. When performed early in life, HSCT significantly improves the prognosis, offering a chance for long-term survival and normal immune function.

Gene Therapy

Emerging gene therapy approaches show promise in correcting the genetic defect in WAS and potentially curing the condition. While still in the experimental phase, gene therapy shows potential to enhance the prognosis for future patients.

Quality of Life

With appropriate treatment and management, individuals with WAS can lead relatively normal lives. This includes regular medical follow-up, supportive therapies, and management of complications.

Life Expectancy

The life expectancy for individuals with WAS has improved with advancements in medical care, including HSCT and better infection control. However, the prognosis can still be guarded for those with severe forms of the disease or who develop serious complications.

Overall, early diagnosis and a comprehensive, multidisciplinary approach to treatment are essential for improving the outlook for individuals with Wiskott-Aldrich syndrome. Consistent follow-up with healthcare providers and continuous monitoring for complications are essential parts of effective management.

CONCLUSION

Wiskott-Aldrich syndrome (WAS) is a rare genetic disorder that predominantly impacts males due to its X-linked inheritance pattern. Effective management requires an interprofessional team approach, involving specialists in hematology, dermatology, pathology, infectious diseases, genetics, nursing, and pharmacy. Diagnosis is based on clinical and laboratory findings, confirmed through genetic testing.

Treatment includes both conventional and supportive care measures. Prophylactic antibiotics are used to prevent infections, and platelet transfusions are administered to manage life-threatening hemorrhages. Intravenous immunoglobulin (IVIG) therapy is indicated for patients with antibody deficiencies. Currently, hematopoietic stem cell transplantation (HSCT) is the sole curative therapy available for Wiskott-Aldrich syndrome (WAS).

Continuous monitoring for infections, bleeding episodes, autoimmune manifestations, and signs of malignancies is essential. This involves regular clinical evaluations, laboratory tests, and, when necessary, imaging studies. Dermatological manifestations, such as eczema, require ongoing management. Living with a chronic and potentially life-threatening condition like WAS can impact the psychological well-being of patients and their families.

Psychosocial support services, such as counseling and participation in support groups, can assist in managing emotional and social difficulties. Genetic counselors provide invaluable support to families by explaining the genetic basis of WAS, discussing inheritance patterns, and offering guidance on family planning options. Even after successful HSCT or other treatments, long-term monitoring and follow-up care are essential to assess for potential complications, monitor immune reconstitution, and optimize overall health and well-being.

REFERENCES:

1. Boston Children's Hospital. Wiskott-Aldrich Syndrome. Retrieved May 20, 2024, from https://www.childrenshospital.org/conditions/wiskott-aldrich-syndrome.
2. Kanegane, H., & Tsukada, S. (2019). Wiskott-Aldrich Syndrome. In GeneReviews®. University of Washington, Seattle. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK539838.
3. MedlinePlus. Wiskott-Aldrich syndrome. Retrieved from https://medlineplus.gov/genetics/condition/wiskott-aldrich-syndrome/#causes
4. Stray-Pedersen A, Abrahamsen TG, Frøland SS. Primary immunodeficiency diseases in Norway. Journal of clinical immunology. 2000 Nov; 20:477-85.
5. Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function. Disease markers. 2010;29(3-4):157-75. [PMC free article] [PubMed]
6. Malinova D, Fritzsche M, Nowosad CR, Armer H, Munro PM, Blundell MP, Charras G, Tolar P, Bouma G, Thrasher AJ. WASp-dependent actin cytoskeleton stability at the dendritic cell immunological synapse is required for extensive, functional T cell contacts. Journal of Leucocyte Biology. 2016 May;99(5):699-710. [PMC free article] [PubMed]
7. Dupré L, Aiuti A, Trifari S, Martino S, Saracco P, Bordignon C, Roncarolo MG. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity. 2002 Aug 1;17(2):157-66. [PubMed]
8. Meyer-Bahlburg A, Becker-Herman S, Humblet-Baron S, Khim S, Weber M, Bouma G, Thrasher AJ, Batista FD, Rawlings DJ. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood, The Journal of the American Society of Hematology. 2008 Nov 15;112(10):4158-69.
9. Gismondi A, Cifaldi L, Mazza C, Giliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood. 2004 Jul 15;104(2):436-43.
10. Maillard MH, Cotta-de-Almeida V, Takeshima F, Nguyen DD, Michetti P, Nagler C, Bhan AK, Snapper SB. The Wiskott-Aldrich syndrome protein is required for the function of CD4+ CD25+ Foxp3+ regulatory T cells. The Journal of experimental medicine. 2007 Feb 19;204(2):381-91.
11. Burns S, Thrasher AJ, Blundell MP, Machesky L, Jones GE. Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation. Blood, The Journal of the American Society of Hematology. 2001 Aug 15;98(4):1142-9.
12. Zicha, Brickell, Kinnon, Thrasher. Chemotaxis of macrophages is abolished in the Wiskott-Aldrich syndrome. British journal of haematology. 1998 Jun;101(4):659-65.
13. Mahlaoui N, Pellier I, Mignot C, Jais JP, Bilhou-Nabéra C, Moshous D, Neven B, Picard C, de Saint-Basile G, Cavazzana-Calvo M, Blanche S. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood, The Journal of the American Society of Hematology. 2013 Feb 28;121(9):1510-6.

14. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. The Journal of pediatrics. 1994 Dec 1;125(6):876-85.
15. Devriendt K, Kim AS, Mathijs G, Frints SG, Schwartz M, Van den Oord JJ, Verhoef GE, Boogaerts MA, Fryns JP, You D, Rosen MK. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nature genetics. 2001 Mar;27(3):313-7.
16. Notarangelo LD, Mazza C, Giliani S, D'Aria C, Gandellini F, Ravelli C, Locatelli MG, Nelson DL, Ochs HD, Notarangelo LD. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood, The Journal of the American Society of Hematology. 2002 Mar 15;99(6):2268-9.
17. Albert MH, Bittner TC, Nonoyama S, Notarangelo LD, Burns S, Imai K, Espanol T, Fasth A, Pellier I, Strauss G, Morio T. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood, The Journal of the American Society of Hematology. 2010 Apr 22;115(16):3231-8.
18. Chiang SC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M. Screening for Wiskott-Aldrich syndrome by flow cytometry. Journal of Allergy and Clinical Immunology. 2018 Jul 1;142(1):333-5.
19. Snover DC, Frizzera G, Spector BD, Perry III GS, Kersey JH. Wiskott-Aldrich syndrome: histopathologic findings in the lymph nodes and spleens of 15 patients. Human Pathology. 1981 Sep 1;12(9):821-31.
20. Blaese RM, Strober W, Levy AL, Waldmann TA. Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. J Clin Invest. 1971 Nov;50(11):2331-8.
21. Gerrits AJ, Leven EA, Frelinger III AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood, The Journal of the American Society of Hematology. 2015 Sep 10;126(11):1367-78.